

## <u>NEWS RELEASE</u> 31<sup>st</sup> October 2014, Mumbai - India

### Performance Highlights.

# Marksans Consolidated Revenue up by 36.55%, PAT up by 45.99% in First Half of FY 2014-15

- Consolidated Revenue grew by 36.55% to Rs 412.80 crores in first half of FY 2014-15.
- EBITDA grew by 52.59% to Rs 93.74 crores for first half of FY 2014-15.
   EBITDA margin grew to 22.70% from 20.13% for the half year.
- Consolidated Net Profit was Rs 56.63 crores for the first half of FY 2014-15.
- Post Tax profits up by 45.99% over previous year same period.

### **Business Highlights**

- Europe, UK Formulation business grew at 42.96% to Rs. 271.20 crores from Rs. 189.70 crores during first half of FY 2014-15.
- US & North America Formulation business grew at 46.70% to Rs.76.46 crores from Rs. 52.12 crores during first half of FY 2014-15.
- Company achieved revenue of Rs. 41.10 crores from Australia & NZ Formulation business.
- Rest of World (Asia, Africa & CIS) Formulation business grew at 5.07% to Rs. 24.04 crores from Rs. 22.88 crores during first half of FY 2014-15.

Revenue Figures - Consolidated

R., 172 H. mays. Sugar See Is the	INR in crores		
a fact, Amely than the Control of the Amely and Amely than the Amely and Ame	First half FY 2014-15	First half FY 2013-14	Growth %
Europe, UK - Formulations	271.20	189.70	42.96%
US & North America - Formulations	76.46	52.12	46.70%
Australia & NZ - Formulations	41.10	37.60	9.31%
Rest of World(ROW) - Africa, Asia & CIS	24.04	22.88	5.07%
Consolidated Revenue from operations	412.80	302.30	36.55%

www.marksanspharma.com

CIN: L24110MH1992PLC066364



## **About Marksans Pharma Limited**

Marksans Pharma Limited(www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK MKRA, Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Limited

11<sup>th</sup> Floor, Grandeur, Opp Gundecha Symphony, Veera Desai Extension Road,
Oshiwara, Andheri – West, Mumbai – 400 053, India
Tel:- +91 22 4001 2000, ax:- +91 22 4001 2011

CIN: L24110MH1992PLC066364

www.marksanspharma.com